Sean Barbour

3.6k citations

41 papers · 456 indexed · 1 hit paper · h-index 11

Impact in

Nephrology top 2%
- Renal Diseases and Glomerulopathies
- Chronic Kidney Disease and Diabetes
Internal Medicine top 10%
- Venous Thromboembolism Diagnosis and Management

Papers in

Nephrology 32
- Renal Diseases and Glomerulopathies 31
- Chronic Kidney Disease and Diabetes 10
Transplantation 2

Co-authors: Heather N. Reich W E Wilkins Daniel Cattran Michelle Hladunewich Taewoo Lee J. Charles Jennette Ronald J. Falk Susan L. Hogan
Journals: Journal of the American Society of Nephrology (10 papers)Nephrology Dialysis Transplantation (8 papers)Kidney International Reports (4 papers)Current Opinion in Nephrology & Hypertension (3 papers)Canadian Journal of Kidney Health and Disease (3 papers)
Partner nations: Canada United States United Kingdom

In The Last Decade

Sean Barbour

32 papers receiving 444 citations

Hit Papers

align trajectories log scale

A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy 2024 · 51 citations

Peers

Countries citing papers authored by Sean Barbour

Since Specialization

Citations

This map shows the geographic impact of Sean Barbour's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sean Barbour with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sean Barbour more than expected).

Fields of papers citing papers by Sean Barbour

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sean Barbour. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sean Barbour. The network helps show where Sean Barbour may publish in the future.

Co-authors

The 25 scholars most cited alongside Sean Barbour, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sean Barbour Line = papers co-authored together Sean Barbour links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Questions and Caveats in Antigen-Defined Membranous Nephropathy Journal of the American Society of Nephrology ·Nicole K. Andeen, Vanderlene L. Kung, Rupali S. Avasare, Sean Barbour, Megan Griffith, Eric H. Olender, Candice Roufosse	2025	0
2	WCN25-844 FELZARTAMAB FOR IgA NEPHROPATHY: FINAL RESULTS OF THE IGNAZ STUDY Kidney International Reports ·Uptal D. Patel, Patti M. Yorks, Jonathan Barratt, Richard Lafayette, Brian S. Schwartz, Paul T. Manser, Stefanie Maria Wagner, P Ngassam, Matthew DeVos, Hanchuan Dong, Sean Barbour	2025	0
3	A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy Kidney International ·Richard Lafayette, Sean Barbour, Rubeen Israni, Xuelian Wei, Necmi Eren, Jürgen Floege, Vivekanand Jha, Sung Gyun Kim, Bart Maes, Richard Phoon, Harmeet Singh, Vladimı́r Tesař, Celia J. F. Lin, Jonathan Barratt Hit paper breakdown →	2024	51
4	Phase II Results of an Investigational RNA Therapeutic to Complement Factor B, IONIS-FB-LRx, for Treatment of IgA Nephropathy Journal of the American Society of Nephrology ·Sean Barbour, Michelle Hladunewich, Angela Makris, Sven‐Jean Tan, Richard A. Robson, Muh Geot Wong, 定浩黒岡, Ashley Frazer‐Abel, P V Rollason, A. H. Abney, Richard S. Geary, Eugene Schneider, Jon Ruckle, Michael L. McCaleb, Мартынова Елена Николаевна	2024	0
5	Long-Term Results from the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgA Nephropathy (IgAN) Journal of the American Society of Nephrology ·Jonathan Barratt, Sean Barbour, Robert Brenner, Kerry Cooper, Xuelian Wei, Necmi Eren, Jürgen Floege, Vivekanand Jha, Sung Gyun Kim, Bart Maes, Richard Phoon, Harmeet Singh, Vladimı́r Tesař, Daiki Okuzono	2024	1
6	New therapies for immunoglobulin A nephropathy: what's the standard of care in 2023? Current Opinion in Nephrology & Hypertension ·Bryce Barr, Sean Barbour	2024	2
7	Are patients with primary glomerular disease at increased risk of malignancy? Nephrology Dialysis Transplantation ·Jialin Han, Yinshan Zhao, Mark Canney, Mohammad Atiquzzaman, Paul Keown, Adeera Levin, Sean Barbour	2023	3
8	An Exploratory Trial of an Investigational RNA Therapeutic, IONIS-FB-LRx, for Treatment of IgA Nephropathy Journal of the American Society of Nephrology ·Sean Barbour, Michelle Hladunewich, Dominik Andrae, Angela Makris, Richard A. Robson, Sven‐Jean Tan, Muh Geot Wong, Ashley Frazer‐Abel, Qingqing Yang, P V Rollason, A. H. Abney, Jon Ruckle, Eugene Schneider, Richard S. Geary, Filippo Canducci, Michael L. McCaleb	2022	4
9	<p>Clusterin Deficiency Predisposes C57BL/6j Mice to Cationic Bovine Serum Albumin-Induced Glomerular Inflammation</p> Journal of Inflammation Research ·Pengcheng Sun, Shijian Feng, Qiunong Guan, Hans Adomat, Sean Barbour, Martin Gleave, Christopher Nguan, Wanhai Xu, Caigan Du	2020	5
10	Effects of the SGLT2 Inhibitor Dapagliflozin on Proteinuria in Non-Diabetic Patients with Chronic Kidney Disease (DIAMOND): A Randomised Double Blind Cross-Over Trial SSRN Electronic Journal ·David Cherney, Claire C. J. Dekkers, Sean Barbour, Daniel C. Cattran, Abdul Halim Abdul Gafor, Peter J. Greasley, Gozewijn D. Laverman, Soo Kun Lim, Gian Luca Di Tanna, Heather N. Reich, Marc Vervloet, Muh Geot Wong, Katerine Cañon Lemus, Hiddo J.L. Heerspink, Margot L. Richters	2020	2
11	A propensity score matched analysis shows no adverse effect of early steroid withdrawal in non-diabetic kidney transplant recipients with and without glomerulonephritis Kidney International ·Sean Barbour, Ognjenka Djurdjev, John S. Gill, Jianghu Dong, Jagbir Gill	2019	7
12	15th International Symposium on IgANephropathy – IIgANN 2018, Buenos Aires, September 27-29, 2018: Summaries Kidney Diseases ·Sean Barbour, Ruxandra Diaconu, Daniel Cattran, Mark Haas, James Mirocha, Évangéline Pillebout, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2018	1
13	An update on predicting renal progression in IgA nephropathy Current Opinion in Nephrology & Hypertension ·Sean Barbour, Heather N. Reich	2018	39
14	An update on the treatment of IgA nephropathy Current Opinion in Nephrology & Hypertension ·Sean Barbour, John Feehally	2017	10
15	Advances in the Understanding of Complement Mediated Glomerular Disease: Implications for Recurrence in the Transplant Setting American Journal of Transplantation ·Sean Barbour, John S. Gill	2015	18
16	The need for improved uptake of the KDIGO glomerulonephritis guidelines into clinical practice in Canada: a survey of nephrologists Clinical Kidney Journal ·Sean Barbour, 直樹菊地, Jagbir Gill, Gabriela Espino-Hernández, Heather N. Reich, Adeera Levin	2014	14
17	An overview of the British Columbia Glomerulonephritis network and registry: integrating knowledge generation and translation within a single framework BMC Nephrology ·Sean Barbour, Monica Beaulieu, Jagbir Gill, Ognjenka Djurdjev, Heather N. Reich, Adeera Levin	2013	19
18	Metastatic signet-ring cell cancer of the bladder responding to chemotherapy with capecitabine: case report and review of literature Canadian Urological Association Journal ·Jorg Michels, Sean Barbour, Masoud Gamiel Ahmed Adli, Kim N.	2013	9
19	Venous Thromboembolism in Patients with Membranous Nephropathy Clinical Journal of the American Society of Nephrology ·Sophia Lionaki, Vimal K. Derebail, Susan L. Hogan, Sean Barbour, Taewoo Lee, Michelle Hladunewich, Allen Greenwald, Yichun Hu, Caroline E. Jennette, J. Charles Jennette, Ronald J. Falk, Daniel Cattran, Patrick H. Nachman, Heather N. Reich	2011	138
20	Group VI Phospholipases A2: Homeostatic Phospholipases with Significant Potential as Targets for Novel Therapeutics Current Drug Targets ·W E Wilkins, Sean Barbour	2008	42

About Sean Barbour

Sean Barbour is a scholar working on Nephrology, Transplantation, Hematology, Rheumatology and Genetics, having authored 41 papers that have together received 456 indexed citations. Recurring topics across this work include Renal Diseases and Glomerulopathies (31 papers), Chronic Kidney Disease and Diabetes (10 papers), Vasculitis and related conditions (8 papers), Systemic Lupus Erythematosus Research (6 papers), Autoimmune Bullous Skin Diseases (5 papers), Chronic Lymphocytic Leukemia Research (4 papers), Platelet Disorders and Treatments (4 papers) and Diabetes Treatment and Management (3 papers). The work is most often cited by research in Nephrology (326 citations), Internal Medicine (47 citations), Transplantation (29 citations), Hematology (78 citations) and Genetics (61 citations). Sean Barbour has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Heather N. Reich, W E Wilkins, Daniel Cattran, Michelle Hladunewich, Taewoo Lee, J. Charles Jennette, Ronald J. Falk, Susan L. Hogan, Allen Greenwald and John S. Gill. Their work appears in journals such as Journal of the American Society of Nephrology, Nephrology Dialysis Transplantation, Kidney International Reports, Current Opinion in Nephrology & Hypertension and Canadian Journal of Kidney Health and Disease.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact